

## Intercept Pharmaceuticals Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 11-Dec-2012

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

# ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

    Phase 3 Clinical..... 11

    Discovery..... 17

[Return to Table of Contents](#)

# Intercept Pharmaceuticals Inc

## COMPANY OVERVIEW

|  |  |
|--|--|
| <b>Company Name</b>                          | Intercept Pharmaceuticals Inc  |
| <b>Parent Company Name</b>                   | Genextra SpA   |
| <b>Website</b>                               | <a href="http://www.interceptpharma.com/">http://www.interceptpharma.com/</a>  |
| <b>Country</b>                               | US   |
| <b>Number of Drugs in Active Development</b> | 4  |
| <b>Number of Inactive Drugs</b>              | 0  |
| <b>Number of Patents as Owner</b>            | 10   |
| <b>Number of Patents as Third Party</b>      | 0  |
| <b>Number of Deals</b>                       | 4  |
| <b>Key Indications</b>                       | Metabolic disorder,Non-insulin dependent diabetes,Diabetic nephropathy,Diarrhea,Fibrosis,Non-alcoholic steatohepatitis,Portal hypertension,Primary biliary cirrhosis,Gastrointestinal disease,Inflammatory disease,Liver disease,Renal disease |
| <b>Key Target-based Actions</b>              | G-protein coupled bile acid receptor 1 agonist,Farnesoid X receptor agonist,G-protein coupled bile acid receptor 1 modulator,Farnesoid X receptor modulator  |
| <b>Key Technologies</b>                      | Small molecule therapeutic,Oral formulation,Systemic formulation unspecified   |

## COMPANY PROFILE

### SUMMARY

Intercept Pharmaceuticals Inc, headquartered in New York City, NY, is focused on the development of small-molecule drugs for the treatment of chronic liver and metabolic diseases. In May 2006, Genextra acquired Intercept Pharmaceuticals.

### FINANCIAL

In October 2012, the company announced the pricing of its initial public offering of 5,000,000 shares of common stock, at a price of \$15 per share, before underwriting discounts. The underwriters were issued a 30-day option to purchase up to an additional 750,000 shares of common stock from Intercept. At that time, the company's shares were expected to begin trading on NASDAQ , on October 11, 2012 under the trading symbol ICPT; later that month, the underwriters purchased the additional shares. The sale of the shares was closed on October 16, 2012.

In September 2012, the company filed a form S-1 registration statement with the US SEC for a proposed IPO of its common stock shares. All the shares would be offered by Intercept, and might not be sold until the registration statement had been effective. At that time, the number of shares and price range for the offering was not determined.

In August 2012, Intercept completed a \$30 million series C preferred stock financing.

In January 2010, Intercept raised \$25 million from a preferred series B financing by its majority shareholder, Genextra.

In July 2008, the company raised \$25 million in equity financing.

In May 2006, Intercept raised \$41 million in equity financing.

In May 2005, Intercept completed a \$1.3 million convertible debt financing round.

In August 2004, Intercept completed a \$3 million first round financing. It was to use the proceeds to complete its acquisition of INT-747 and related intellectual property and to complete preclinical trials of the drug.

[Return to Table of Contents](#)




# PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

## Drugs by Indication Table

| Indication               | Active | Inactive | Total |
|--------------------------|--------|----------|-------|
| Metabolic disorder       | 2      | 1        | 3     |
| Gastrointestinal disease | 2      | 0        | 2     |
| Inflammatory disease     | 2      | 0        | 2     |
| Endocrine disease        | 1      | 0        | 1     |
| Genitourinary disease    | 1      | 0        | 1     |
| Cardiovascular disease   | 1      | 0        | 1     |
| Immune disorder          | 1      | 0        | 1     |

## Drugs by Highest Status

### Active Drugs by Highest Status Chart



## Drugs by Highest Status Table

| Development Status | Number of Drugs |
|--------------------|-----------------|
| Phase 3 Clinical   | 1               |
| Discovery          | 3               |

[Return to Table of Contents](#)

## DEALS

| Deal Type                                    | Principal |          | Partner |          | Total |
|--|-----------|----------|---------|----------|-------|
|  | Active    | Inactive | Active  | Inactive |       |
| Drug - CRADA                                 | 1         | 0        | 0       | 0        | 1     |
| Drug - Development/Commercialization License | 2         | 0        | 1       | 0        | 3     |

## CLINICAL TRIALS

### Trials by Condition Studied

| Condition Studied        | Ongoing | All |
|--------------------------|---------|-----|
| Gastrointestinal disease | 1       | 5   |
| Immune disorder          | 1       | 3   |
| Endocrine disease        | 0       | 2   |
| Metabolic disorder       | 0       | 2   |
| Inflammatory disease     | 0       | 2   |
| Cardiovascular disease   | 0       | 1   |

### Trials by Phase

| Phase   | Ongoing | All |
|---------|---------|-----|
| Phase 3 | 1       | 1   |
| Phase 2 | 0       | 4   |
| Phase 1 | 0       | 1   |

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

| Indication      | As Owner | As Third Party | Total |
|-----------------|----------|----------------|-------|
| Immune disorder | 3        | 0              | 3     |
| Neoplasm        | 3        | 0              | 3     |
| Ocular disease  | 1        | 0              | 1     |

[Return to Table of Contents](#)





|                          |    |   |    |
|--------------------------|----|---|----|
| Metabolic disorder       | 9  | 0 | 9  |
| Neurological disease     | 1  | 0 | 1  |
| Cardiovascular disease   | 8  | 0 | 8  |
| Endocrine disease        | 3  | 0 | 3  |
| Genitourinary disease    | 7  | 0 | 7  |
| Gastrointestinal disease | 10 | 0 | 10 |
| Nutritional disorder     | 5  | 0 | 5  |
| Inflammatory disease     | 5  | 0 | 5  |

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### obeticholic acid

#### obeticholic acid SNAPSHOT

|                             |  |
|-----------------------------|--|
| <b>Drug Name</b>            | obeticholic acid   |
| <b>Key Synonyms</b>         | obeticholic acid   |
| <b>Originator Company</b>   | Universita di Perugia  |
| <b>Active Companies</b>     | Intercept Pharmaceuticals Inc;Dainippon Sumitomo Pharma Co Ltd                                     |
| <b>Inactive Companies</b>   | Universita di Perugia  |
| <b>Highest Status</b>       | Phase 3 Clinical   |
| <b>Active Indications</b>   | Diarrhea;Liver disease;Primary biliary cirrhosis;Non-alcoholic steatohepatitis;Portal hypertension |
| <b>Target-based Actions</b> | Farnesoid X receptor agonist   |
| <b>Other Actions</b>        | Bile acid modulator;Antihypertensive;Antidiarrhoeal  |
| <b>Technologies</b>         | Oral formulation;Small molecule therapeutic  |
| <b>Last Change Date</b>     | 30-Nov-2012  |

#### obeticholic acid DEVELOPMENT PROFILE

#### SUMMARY

Intercept Pharmaceuticals (a wholly-owned subsidiary of Genextra), under license from the University of Perugia, is developing the farnesoid X receptor (FXR) agonist obeticholic acid (INT-747; UPF-747; 6ECDCA, OCA) for the potential once-daily oral treatment of portal hypertension and liver diseases, such as primary biliary cirrhosis (PBC), bile acid diarrhea and non-alcoholic fatty liver disease (NAFLD), including non-alcoholic steatohepatitis (NASH) . Intercept's Asian licensee Dainippon Sumitomo Pharma is developing the drug (as DSP-1747) for PBC, NASH and other chronic liver diseases. In March 2011, Intercept initiated a phase II/III NASH trial. By October 2012, a phase II trial for NASH was underway in Japan. In January 2012, a phase III PBC trial began in the US. In March 2011, a phase III trial was to be initiated in Europe. In August 2012, the drug was in phase IIa for portal hypertension ; in November 2012, data were reported. In July 2012, a phase IIa trial for bile acid diarrhea was initiated. At that time, the trial was expected to be completed in October 2012.

Previously, the University of Perugia was investigating the compound for the potential treatment of cholestasis. By June 2010, Intercept was also investigating a series of preclinical backup and follow-on FXR compounds, including other bile acid derived and synthetic small molecule compounds, which were being optimized.

#### obeticholic acid DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS

[Return to Table of Contents](#)



| Company                          | Indication                    | Country        | Development Status | Date        |
|----------------------------------|-------------------------------|----------------|--------------------|-------------|
| Intercept Pharmaceuticals Inc    | Non-alcoholic steatohepatitis | US             | Phase 3 Clinical   | 03-Mar-2011 |
| Intercept Pharmaceuticals Inc    | Primary biliary cirrhosis     | US             | Phase 3 Clinical   | 06-Jan-2011 |
| Dainippon Sumitomo Pharma Co Ltd | Non-alcoholic steatohepatitis | Japan          | Phase 2 Clinical   | 31-Oct-2012 |
| Intercept Pharmaceuticals Inc    | Diarrhea                      | UK             | Phase 2 Clinical   | 31-Jul-2012 |
| Intercept Pharmaceuticals Inc    | Portal hypertension           | Western Europe | Phase 2 Clinical   | 13-Aug-2012 |
| Dainippon Sumitomo Pharma Co Ltd | Liver disease                 | China          | Discovery          | 30-Mar-2011 |
| Universita di Perugia            | Jaundice                      | Italy          | Discontinued       | 12-Aug-2004 |
| Universita di Perugia            | Liver disease                 | Italy          | Discontinued       | 12-Aug-2004 |

### obeticholic acid CHEMICAL STRUCTURES

|   |                   |
|---|-------------------|
| CAS Registry Number:  | Confidence Level: |
| 459789-99-2   | 2                 |
|  |                   |
| Name  | Type              |
| obeticholic acid  | INN; USAN         |
| INT-747   | Research Code     |
| 6ECDCA  |                   |

[Return to Table of Contents](#)

## obeticholic acid DRUG NAMES

| Names                                    | Type          |
|--|---------------|
| UPF-747                                  | Research Code |
| INT-747                                  | Research Code |
| FXR agonists, Intercept                  |               |
| farnesoid X receptor agonists, Intercept |               |
| 6ECDCA                                   |               |
| obeticholic acid                         | INN, USAN     |
| DSP-1747                                 | Research Code |
| OCA, Intercept                           |               |

## obeticholic acid CLINICAL TRIALS

### Trials by Phase and Condition Studied

| Phase 4 Clinical               |     | Phase 3 Clinical |     | Phase 2 Clinical |     | Phase 1 Clinical |     | Phase Unspecified |     | Total    |     |
|--------------------------------|-----|------------------|-----|------------------|-----|------------------|-----|-------------------|-----|----------|-----|
| On-going                       | All | On-going         | All | On-going         | All | On-going         | All | On-going          | All | On-going | All |
| Non-alcoholic steatohepatitis  |     |                  |     |                  |     |                  |     |                   |     |          |     |
| 0                              | 0   | 0                | 0   | 2                | 3   | 0                | 1   | 0                 | 0   | 2        | 4   |
| Primary biliary cirrhosis      |     |                  |     |                  |     |                  |     |                   |     |          |     |
| 0                              | 0   | 1                | 1   | 0                | 1   | 0                | 1   | 0                 | 0   | 1        | 3   |
| Non-insulin dependent diabetes |     |                  |     |                  |     |                  |     |                   |     |          |     |
| 0                              | 0   | 0                | 0   | 0                | 1   | 0                | 1   | 0                 | 0   | 0        | 2   |
| Diarrhea                       |     |                  |     |                  |     |                  |     |                   |     |          |     |
| 0                              | 0   | 0                | 0   | 1                | 1   | 0                | 0   | 0                 | 0   | 1        | 1   |
| Portal hypertension            |     |                  |     |                  |     |                  |     |                   |     |          |     |
| 0                              | 0   | 0                | 0   | 0                | 1   | 0                | 0   | 0                 | 0   | 0        | 1   |
| Biliary cirrhosis              |     |                  |     |                  |     |                  |     |                   |     |          |     |
| 0                              | 0   | 0                | 0   | 0                | 1   | 0                | 0   | 0                 | 0   | 0        | 1   |
| Liver disease                  |     |                  |     |                  |     |                  |     |                   |     |          |     |
| 0                              | 0   | 0                | 0   | 0                | 0   | 0                | 1   | 0                 | 0   | 0        | 1   |

[Return to Table of Contents](#)



## Total Trials by Phase and Status

| Phase 4 Clinical          |     | Phase 3 Clinical |     | Phase 2 Clinical |     | Phase 1 Clinical |     | Phase Unspecified |     | Total    |     |
|---------------------------|-----|------------------|-----|------------------|-----|------------------|-----|-------------------|-----|----------|-----|
| On-going                  | All | On-going         | All | On-going         | All | On-going         | All | On-going          | All | On-going | All |
| Total by Phase and Status |     |                  |     |                  |     |                  |     |                   |     |          |     |
| 0                         | 0   | 1                | 1   | 3                | 7   | 0                | 1   | 0                 | 0   | 4        | 9   |

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0


## obeticholic acid DEALS AND PATENTS

### DEALS

#### Deals by Parent Company Chart



Active Deals  
Total: 3




[Return to Table of Contents](#)

### Deals by Parent Company Table

| Company Name             | Principal |          | Partner |          | Total |
|--------------------------|-----------|----------|---------|----------|-------|
|                          | Active    | Inactive | Active  | Inactive |       |
| Genextra SpA             | 2         | 0        | 1       | 0        | 3     |
| US Government            | 0         | 0        | 1       | 0        | 1     |
| Sumitomo Chemical Co Ltd | 0         | 0        | 1       | 0        | 1     |
| Universita di Perugia    | 1         | 0        | 0       | 0        | 1     |

### Deals by Type Chart




### Deals by Type Table

| Deal Type                                    | Active | Inactive | Total |
|--|--------|----------|-------|
| Drug - Development/Commercialization License | 2      | 0        | 2     |
| Drug - CRADA                                 | 1      | 0        | 1     |

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

| Company Name                         | As Owner | As Third Party | Total |
|--------------------------------------|----------|----------------|-------|
| Genextra SpA                         | 5        | 0              | 5     |
| Sumitomo Chemical Co Ltd             | 4        | 0              | 4     |
| Universita di Perugia                | 1        | 2              | 3     |
| GlaxoSmithKline plc                  | 2        | 0              | 2     |
| City of Hope                         | 1        | 0              | 1     |
| Individual                           | 1        | 0              | 1     |
| Celldex Therapeutics Inc             | 1        | 0              | 1     |
| Royal College of Surgeons in Ireland | 1        | 0              | 1     |
| Erregierre Industria Chimica SpA     | 1        | 0              | 1     |
| US Government                        | 1        | 0              | 1     |

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

| Drug Relationship        | Total |
|--------------------------|-------|
| New use                  | 4     |
| Process                  | 2     |
| Component of Combination | 1     |
| Product (derivative)     | 1     |
| Product                  | 1     |

[Return to Table of Contents](#)



## INT-767

### INT-767 SNAPSHOT

|                      |   |
|----------------------|---|
| Drug Name            | INT-767   |
| Key Synonyms         |   |
| Originator Company   | Intercept Pharmaceuticals Inc   |
| Active Companies     | Intercept Pharmaceuticals Inc   |
| Inactive Companies   |   |
| Highest Status       | Discovery   |
| Active Indications   | Diabetic nephropathy;Fibrosis   |
| Target-based Actions | Farnesoid X receptor agonist;G-protein coupled bile acid receptor 1 agonist |
| Other Actions        |   |
| Technologies         | Systemic formulation unspecified;Small molecule therapeutic                 |
| Last Change Date     | 13-Aug-2012   |

### INT-767 DEVELOPMENT PROFILE

#### SUMMARY

Intercept is investigating INT-767, a dual farnesoid X receptor (FRX) and TGR5 agonist for the potential treatment of fibrosis and chronic kidney diseases including diabetic nephropathy . In June 2010, the drug was in preclinical development ; in August 2012, this was still the case.

Intercept was previously investigating INT-767, for the potential treatment of metabolic diseases. However, no further development was reported for this indication since August 2012 .

Intercept was also previously investigating FRX and TGR5 bile acid derived back ups. In June 2010, the compounds were under preclinical development. However, no further development was reported since August 2012 .

### INT-767 DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS

| Company                       | Indication           | Country | Development Status      | Date        |
|-------------------------------|----------------------|---------|-------------------------|-------------|
| Intercept Pharmaceuticals Inc | Diabetic nephropathy | US      | Discovery               | 17-Dec-2007 |
| Intercept Pharmaceuticals Inc | Fibrosis             | US      | Discovery               | 01-Jan-2010 |
| Intercept Pharmaceuticals Inc | Metabolic disorder   | US      | No Development Reported | 13-Aug-2012 |

[Return to Table of Contents](#)



## INT-767 CHEMICAL STRUCTURES

| CAS Registry Number:   | Confidence Level: |
|--|-------------------|
|  | 4                 |
|  |                   |
| Name   | Type              |
| INT-767  | Research Code     |

## INT-767 DRUG NAMES

| Names  | Type          |
|--|---------------|
| INT-767  | Research Code |
| farnesoid X receptor (FXR)/TGR5 agonist (diabetic nephropathy), Intercept        |               |
| farnesoid X receptor (FXR)/TGR5 agonist (metabolic disorder/fibrosis), Intercept |               |

[Return to Table of Contents](#)

## TGR5 agonists (type 2 diabetes), Servier/ Intercept Pharmaceuticals

### TGR5 agonists (type 2 diabetes), Servier/ Intercept Pharmaceuticals SNAPSHOT

|                      |   |
|----------------------|---|
| Drug Name            | TGR5 agonists (type 2 diabetes), Servier/ Intercept Pharmaceuticals |
| Key Synonyms         |   |
| Originator Company   | Intercept Pharmaceuticals Inc                                       |
| Active Companies     | Servier;Intercept Pharmaceuticals Inc                               |
| Inactive Companies   |   |
| Highest Status       | Discovery   |
| Active Indications   | Non-insulin dependent diabetes                                      |
| Target-based Actions | G-protein coupled bile acid receptor 1 agonist                      |
| Other Actions        | Hypoglycemic agent  |
| Technologies         | Small molecule therapeutic  |
| Last Change Date     | 18-Aug-2011   |

### TGR5 agonists (type 2 diabetes), Servier/ Intercept Pharmaceuticals DEVELOPMENT PROFILE

#### SUMMARY

Servier, in collaboration with Intercept Pharmaceuticals, is investigating bile acid analog-based TGR5 agonists for the potential treatment of type 2 diabetes and other metabolic disorders.

### TGR5 agonists (type 2 diabetes), Servier/ Intercept Pharmaceuticals DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

| Company                       | Indication                     | Country | Development Status | Date        |
|-------------------------------|--------------------------------|---------|--------------------|-------------|
| Intercept Pharmaceuticals Inc | Non-insulin dependent diabetes | US      | Discovery          | 09-Aug-2011 |
| Servier                       | Non-insulin dependent diabetes | France  | Discovery          | 09-Aug-2011 |


### TGR5 agonists (type 2 diabetes), Servier/ Intercept Pharmaceuticals DRUG NAMES

| Names   | Type |
|---|------|
| TGR5 agonists (type 2 diabetes), Servier/ Intercept Pharmaceuticals |      |

[Return to Table of Contents](#)

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

| Company Name | Principal |          | Partner |          | Total |
|--------------|-----------|----------|---------|----------|-------|
|              | Active    | Inactive | Active  | Inactive |       |
| Genextra SpA | 1         | 0        | 0       | 0        | 1     |
| Servier      | 0         | 0        | 1       | 0        | 1     |

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

| Deal Type                                    | Active | Inactive | Total |
|--|--------|----------|-------|
| Drug - Development/Commercialization License | 1      | 0        | 1     |

## INT-777

### INT-777 SNAPSHOT

|                      |  |
|----------------------|--|
| Drug Name            | INT-777  |
| Key Synonyms         |  |
| Originator Company   | Intercept Pharmaceuticals Inc                  |
| Active Companies     | Intercept Pharmaceuticals Inc                  |
| Inactive Companies   |  |
| Highest Status       | Discovery                                      |
| Active Indications   | Metabolic disorder                             |
| Target-based Actions | G-protein coupled bile acid receptor 1 agonist |
| Other Actions        |  |
| Technologies         | Oral formulation;Small molecule therapeutic    |
| Last Change Date     | 30-Nov-2012                                    |

### INT-777 DEVELOPMENT PROFILE

#### SUMMARY

Intercept Pharmaceuticals is investigating INT-777, a modified bile acid and TGR5 agonist, for the potential oral treatment of metabolic disorders including diabetes and obesity,. By December 2007, the drug was in preclinical development; in August 2012, this was still the case.

By June 2010, Intercept was also characterizing additional series of backup TGR5 agonists, including other bile acid derived and synthetic small molecule compounds.

### INT-777 DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS

| Company                       | Indication         | Country | Development Status | Date        |
|-------------------------------|--------------------|---------|--------------------|-------------|
| Intercept Pharmaceuticals Inc | Metabolic disorder | US      | Discovery          | 17-Dec-2007 |

### INT-777 CHEMICAL STRUCTURES

[Return to Table of Contents](#)



| CAS Registry Number:   | Confidence Level: |
|--|-------------------|
|  | 3                 |
|  |                   |
| Name   | Type              |
| INT-777  | Research Code     |


INT-777 DRUG NAMES

| Names  | Type          |
|--|---------------|
| TGR5 agonist (oral, metabolic disorder), Intercept |               |
| INT-777  | Research Code |

INT-777 DEALS AND PATENTS

PATENTS

Patents by Parent Company Chart




[Return to Table of Contents](#)

Patents by Parent Company Table

| Company Name | As Owner | As Third Party | Total |
|--------------|----------|----------------|-------|
| Genextra SpA | 2        | 0              | 2     |

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

| Drug Relationship | Total |
|-------------------|-------|
| Product           | 2     |

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

